Anti-HER2 trastuzumab and pertuzumab monoclonal antibodies (mAbs) are examples of FDA-approved adjuvants which are used in combinational therapy or monotherapy to target and kill tumor cells in early breast cancer [5, 6]. The gene discussed is ERBB2; the disease is breast cancer.